NRx reports Q2 2026 results, advances ketamine ANDA and DARPA-backed NRX-101 trial
NRx said FDA raised no drug-related deficiencies in its ketamine ANDA review and disclosed a DARPA prime contract for a Phase 2/3 trial of NRX-101 with robotic TMS.
SEC filing